Showing results (1421-1430 of 1,513) with videos related to
Sort By:
Pageof 152
Journal of Neuro-Oncology|September 23, 2011
Clinical outcome of central nervous system metastases from breast cancer: differences in survival depending on systemic treatmentHee-Jun Kim, Seock-Ah Im, Bhumsuk Keam, et al.Cancers|March 10, 2022
Stereotactic Body Radiation Therapy versus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Propensity Score-Matched AnalysisYoung Seob Shin, Hee Hyun Park, Jin-Hong Park, et al.Cancer Discovery|September 22, 2021
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung CancerPasi A Jänne, Christina Baik, Wu-Chou Su, et al.Cancers|March 1, 2019
Clinical Outcomes of Conversion Surgery after Neoadjuvant Chemotherapy in Patients with Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer: A Single-Center, Retrospective AnalysisChanghoon Yoo, Sang Hyun Shin, Kyu-Pyo Kim, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 21, 2020
Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 StudyRoy S Herbst, Edward B Garon, Dong-Wan Kim, et al.Cancer Research and Treatment|March 14, 2018
Randomized Phase III Trial of Irinotecan Plus Cisplatin versus Etoposide Plus Cisplatin in Chemotherapy-Naïve Korean Patients with Extensive-Disease Small Cell Lung CancerDong-Wan Kim, Hoon-Gu Kim, Joo-Hang Kim, et al.Thoracic Cancer|October 7, 2020
Phase II study of durvalumab and tremelimumab in pulmonary sarcomatoid carcinoma: KCSG-LU16-07Miso Kim, Bhumsuk Keam, Chan-Young Ock, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 1, 2025
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLCPasi A Jänne, Yasushi Goto, Toshio Kubo, et al.Investigational New Drugs|April 5, 2018
Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysisJihoon Kang, Inhwan Hwang, Changhoon Yoo, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 23, 2019
Brigatinib in Crizotinib-Refractory ALK+ NSCLC: 2-Year Follow-up on Systemic and Intracranial Outcomes in the Phase 2 ALTA TrialRudolf M Huber, Karin H Hansen, Luis Paz-Ares Rodríguez, et al.Pageof 152